Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 95

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 95
---
ary
Shares in the United States has fluctuated, and is likely to continue to fluctuate, substantially in response to various factors, some
of which are beyond our control, including limited trading volume. The stock market in general, and the market for pharmaceutical and
biotechnology stocks in particular, have experienced extreme volatility that has often been unrelated to the operating performance of
these companies. As a result of this volatility, investors may not be able to sell their Depositary Shares at or above the price paid
for the Depositary Shares. In addition, there is no current market for our Ordinary Shares and we do not expect to list our Ordinary Shares
on any exchange or have them quoted for trading on any over-the-counter trading system in the foreseeable future.

In addition to the factors
discussed in this “Risk Factors” section, the factors that could cause volatility in the market price of each Depositary
Share include:

| • | the success of competitive products or technologies; |

| • | regulatory actions; |

| • | actual or anticipated changes in our growth rate relative to our competitors; |

| • | announcements by us or our competitors of new products, significant acquisitions, strategic partnerships, 
 joint ventures, collaborations or capital commitments;                                                    |

| • | the progress of preclinical development, laboratory testing and clinical trials of our product candidates 
 or those of our competitors;                                                                              |

| • | the results from our clinical programs and any future trials we may conduct; |

| • | developments in the clinical trials of potentially similar competitive products; |

| • | EMA, MHRA, FDA or international regulatory or legal developments; |

| • | failure of any of our product candidates, if approved, to achieve commercial success; |

| 47 |

| • | developments or disputes concerning patent applications, issued patents or other proprietary intellectual 
 property rights;                                                                                          |

| • | the recruitment or departure of key personnel; |

| • | the level of expenses related to any of our product candidates or clinical development programs; |

| • | litigation or public concern about the safety of our products; |

| • | actual or anticipated changes in estimates as to financial results, development timelines or recommendations 
 by securities analysts;                                                                                      |

| • | actual and anticipated fluctuations in our operating results; |

| • | variations in our financial results or those of companies that are perceived to be similar to us; |

| • | share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; |

| • | announcements or expectations